DE
Therapeutic Areas
Atacama Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| AT-5214 (dexmecamylamine) | Acne Vulgaris (moderate to severe) | Phase 2 |
| Early Stage Programs | Dermatology (unspecified) | Preclinical |
Leadership Team at Atacama Therapeutics
JB
Joseph Baron
Co-Founder, Director & CEO
JR
Jonathan Reis
Co-Founder, Director, Head Corporate Development
MJ
Melissa Joseph
Head of CMC
GH
Garet Heintz
Head of Regulatory
BF
Barry Francis
Head of Quality Assurance
JR
John Ratcliffe
Interim CFO
DB
Dr. Benjamin Daniel
Clinical Trial Investigator